A Bold Investment Strategy Focused on Building on Innovation
3B Future Health Fund supports US and European-based private early-stage, innovative companies in areas of high unmet patient needs.
Guided by our core values, inspired by the needs of patients and with a passion for science and oncology, we leverage our expertise and network to bring life-changing treatments to patients.
We strive to be the preferred partner to select investors and portfolio companies, motivated by a sense of purpose, excellent execution, personal involvement and premium performance.
Looking for companies sharing our core values of QUALITY, INTEGRITY & RESPECT, and a strong passion for bringing new life-changing treatments to patients.
We focus on start-up companies based in Europe, the US and Israel. We support companies with potential first-in-class assets, revolutionary insights, experienced management teams and a strong investor syndicate. We typically make our initial investment in companies raising Series A rounds, but in some cases even earlier.
Team with proven track-record founded on robust due diligence and efficient work processes. Invest only in First Class Science & Technology. 3B FUTURE Health Fund has made 12 investments with one highly profitable exit to date.
10-year fund – Investment in target companies to be held for five to eight years, or fewer if value inflection points are reached which could permit earlier exits.
Focus / Geography
Focus / Geography
100% healthcare, early stage and clinical development stage.
Therapeutic areas with strong unmet patient needs; priority on US and European-based startups focusing mainly on oncology and rare diseases, leveraging the expertise of the team.
Opportunistic investments, made on a case-by-case basis.
Fund comprised of 10-15 companies, up to $12 million investment in each and Board position desirable.
We reserve capital for follow-on rounds.
Our team is building a diversified portfolio designed to balance the risks and optimise potential returns by investing in companies at early and mid-stages of development, with different levels of complexity in science and technology, drug modality agnostic and based across different geographies.View our full portfolio
IDENTIFYING SCIENCE AND TECHNOLOGY WITH THE POTENTIAL TO TRANSFORM PATIENTS’ LIVES
40+ years of building successful
27 January 20223B Future Health promotes Marianne Bjørdal to Partner
29 November 2021FDA Approves New Imaging Drug to Help Identify Ovarian Cancer Lesions
23 November 2021FDA approves sirolimus protein-bound particles for malignant perivascular epithelioid cell tumor
23 November 2021Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)
2 November 2021OncoResponse Announces Initiation of Phase 1 Trial of OR2805 – Human Monoclonal Antibody Derived from Elite Responder to Cancer Immunotherapy – in Patients with Advanced Cancer
26 October 2021GenEp Raises $1.45 Million Seed Financing
6 October 2021OncoResponse Announces Presentations at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021)
26 August 2021Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement
10 August 2021Tesis Labs and Personal Genome Diagnostics Announce Collaboration to Advance Cancer Profiling and Treatment
3 August 2021Personal Genome Diagnostics Appoints Jamie Platt, Ph.D., as Chief Operations Officer
27 July 2021iOnctura Project Evaluating Novel PI3Kδ-inhibitor IOA-244 in Lymphoma to be Co-funded by Innosuisse
20 July 2021iOnctura Announces First Subject Dosed in Healthy Volunteer Study of Next Generation Autotaxin Inhibitor IOA-289
Get in Touch
For further information, please contact us using the form below.
Someone from the team will be in contact in due course.
Thank you for your form submission, we will get in contact with you shortly.